Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processing.

Journal: BMC infectious diseases
PMID: 40217145

Abstract

BACKGROUND: Remdesivir (RDV) was the first antiviral approved for mild-to-moderate COVID-19 and for those patients at risk for progression to severe disease after clinical trials supported its association with improved outcomes. Real-world evidence (RWE) generated by artificial intelligence techniques could potentially expedite the validation of new treatments in future health crises. We aimed to use natural language processing (NLP) and machine learning (ML) to assess the impact of RDV on COVID19-associated outcomes including time to discharge and in-hospital mortality.

Authors

  • José Ramón Arribas López
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), Ciber Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. joser.arribas@salud.madrid.org.
  • María Pilar Ruiz Seco
    Internal Medicine Service, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Francisco Fanjul
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario Son Espases, Fundació Institut de Investigació Sanitaria de Les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Beatriz Díaz Pollán
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), Ciber Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Patricia González Ruano Pérez
    Internal Medicine Service, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Adrián Ferre Beltrán
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario Son Espases, Fundació Institut de Investigació Sanitaria de Les Illes Balears (IdISBa), Palma de Mallorca, Spain.
  • Rosa De Miguel Buckley
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPAZ), Ciber Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Laura Portillo Horcajada
    Hospital Pharmacy, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Cristina De Álvaro Pérez
    Gilead Sciences, Inc, Madrid, Spain.
  • Paulo Jorge Barroso Santos Carvalho
    Gilead Sciences, Inc, Madrid, Spain.
  • Melchor Riera Jaume
    Infectious Diseases Unit, Internal Medicine Service, Hospital Universitario Son Espases, Fundació Institut de Investigació Sanitaria de Les Illes Balears (IdISBa), Palma de Mallorca, Spain.

Keywords

External Resources

Popular Topics
Recent Journals